PMID: 127 LiYZhangS-XYinX-FZhangM-XQiaoJXinX-Het al
#FunctionalMedicine #WeightLoss #Tesofensine #ObesityTreatment #MetabolicHealth To view or add a comment, sign in Latest News : "LDL-C, Lp(a) & Hs-CRP Predict CV Events Synergistically" New UK Biobank data shows LDL-C, Lp(a), and Hs-CRP work together to predict cardiovascular events, even in patients on cholesterol-lowering drugs
Fetal Risk Valproate can cause major congenital malformations, particularly neural tube defects (e.g., spina bifida)
Primary Endpoint: Weight Loss at 72 Weeks The results were striking and clinically significant: Zepbound Group: Participants achieved an average weight reduction of 20.2% at 72 weeks Wegovy Group: Participants achieved an average weight reduction of 13.7% at 72 weeks Relative Difference: Zepbound provided 47% greater relative weight loss compared to Wegovy To put this in practical terms: A patient weighing 250 pounds could expect to lose approximately 50 pounds with Zepbound versus 34 pounds with Wegovy over the same timeframe
Same active ingredient as Wegovy in a different delivery format
She did a great job with my Botox and filler and I'm beyond pleased
